Biophytis to Host Key Opinion Leader Meeting on the Biology of Aging and its
Application in Neuromuscular Diseases
Paris (France), November 27, 2018 - BIOPHYTIS (Euronext Growth Paris: ALBPS), a
clinical-stage biotechnology company specializing in the development of drug
candidates to treat the disabilities caused by age-related degenerative
diseases, will host a Key Opinion Leader (KOL) meeting on the Biology of Aging
and its Application in Neuromuscular Diseases in Geneva, Switzerland on
Wednesday, November 28 at 12:15 PM to 2:00 PM CET.
The meeting will feature a presentation by KOL Professor Jean Mariani, from
Sorbonne University, who will discuss his research behind the biology of aging
and the current treatment landscape for patients with sarcopenia, a
degenerative loss of muscle mass and quality that leads decreased patient
mobility and loss of independence in the aging population. Prof. Mariani will
be available to answer questions at the conclusion of the event.
Professor Jean Mariani is Director of the Institut de la Longévité Charles
Foix [Longevity Institute], and a practitioner at the hospital, director of the
CNRS-UPMC (UMR 7102) Laboratoire de Neurobiologie des Processus Adaptatifs
[Laboratory of Neurobiology of Adaptive Processes]. Professor Jean Mariani is
an expert in neurobiology, central nervous system and pathologies, and
Biophytis's Chief Executive Officer, Stanislas Veillet, will provide an
overview of the Company's lead candidate, SARCONEOS, a MAS receptor activator
that is in clinical development for sarcopenia and Duchenne Muscular Dystrophy,
a fatal genetic disorder that causes progressive muscle weakness.
This event is primarily intended for institutional investors, sell-side
analysts, and business development professionals. Please RSVP in advance if you
plan to attend, as space is limited. For those who are unable to attend in
person, a live webcast and replay will be accessible via the link here. If you
would like to ask a question during the live Q&A, please submit your request
via email link here.
Biophytis SA, founded in 2006, is a biotechnology company specializing in the
development of drug candidates to treat the disabilities caused by age-related
degenerative diseases. Our clinical-stage pipeline is comprised of SARCONEOS, a
MAS receptor activator, to preserve mobility in sarcopenia and Duchenne
muscular dystrophy (DMD) patients and MACUNEOS, a drug that binds PPAR to
prevent vision loss in patients with dry age-related macular degeneration (AMD)
and other degenerative eye diseases, including Stargardt disease.
Biophytis is based in Paris on the Sorbonne Université campus and in
Cambridge, Massachusetts. Biophytis collaborates with expert scientists from
several Sorbonne Université institutes including the Paris Seine Biology
Institute, the Institute of Myology, and the Vision Institute.
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS;
For more information: http://www.biophytis.com
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain
forward-looking statements involving risks and uncertainties. The Company's
actual results could differ substantially from those anticipated in these
statements owing to various risk factors which are described in the Company's
prospectus. This press release has been prepared in both French and English. In
the event of any differences between the two texts, the French language version